1. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. (January 2020) Authors: Yang, Ching-Yao; Liao, Wei-Yu; Ho, Chao-Chi; Chen, Kuan-Yu; Tsai, Tzu-Hsiu; Hsu, Chia-Lin; Su, Kang-Yi; Chang, Yih-Leong; Wu, Chen-Tu; Hsu, Chia-Chi; Liao, Bin-Chi; Hsu, Wei-Hsun; Lee, Jih-Hsiang; Lin, Chia-Chi; Shih, Jin-Yuan; Yang, James C.-H.; Yu, Chong-Jen Journal: European journal of cancer Issue: Volume 124(2020) Page Start: 110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Issue 2 (May 2015) Authors: Tsai, Tzu-Hsiu; Wu, Shang-Gin; Hsieh, Min-Shu; Yu, Chong-Jen; Yang, James Chih-Hsin; Shih, Jin-Yuan Journal: Lung cancer Issue: Volume 88:Issue 2(2015:May) Page Start: 208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. (April 2018) Authors: Liao, Wei-Yu; Ho, Chao-Chi; Tsai, Tzu-Hsiu; Chen, Kuan-Yu; Shih, Jin-Yuan; Yu, Chong-Jen Journal: Lung cancer Issue: Volume 118(2018) Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. (July 2020) Authors: Lin, Yen-Ting; Tsai, Tzu-Hsiu; Wu, Shang-Gin; Liu, Yi-Nan; Yu, Chong-Jen; Shih, Jin-Yuan Journal: Lung cancer Issue: Volume 145(2020) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer. (June 2021) Authors: Hsu, Chia-Lin; Tsai, Tzu-Hsiu; Huang, Chun-Kai; Yang, Ching-Yao; Liao, Wei-Yu; Ho, Chao-Chi; Ruan, Sheng-Yuan; Chen, Kuan-Yu; Shih, Jin-Yuan; Yang, Pan-Chyr Journal: Lung cancer Issue: Volume 156(2021) Page Start: 50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Issue 2 (February 2018) Authors: Lin, Chia-Chi; Shih, Jin-Yuan; Yu, Chong-Jen; Ho, Chao-Chi; Liao, Wei-Yu; Lee, Jih-Hsing; Tsai, Tzu-Hsiu; Su, Kang-Yi; Hsieh, Min-Shu; Chang, Yih-Leong; Bai, Ya-Ying; Huang, Derek De-Rui; Thress, Kenneth S; Yang, James Chih-Hsin Journal: Lancet Issue: Volume 6:Issue 2(2018) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. (October 2022) Authors: Chang, Chia-Ling; Hsieh, Min-Shu; Shih, Jin-Yuan; Lee, Yi-Hsuan; Liao, Wei-Yu; Hsu, Chia-Lin; Yang, Ching-Yao; Chen, Kuan-Yu; Lee, Jih-Hsiang; Ho, Chao-Chi; Tsai, Tzu-Hsiu; Yang, James Chih-Hsin; Yu, Chong-Jen Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗